Bakouny, Ziad

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

Braun, D. A., Hou, Y., Bakouny, Z., Ficial, M., Sant’ Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A. C., Jegede, O. A., Elagina, L., et al. (2020) · Nature Medicine

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 992

Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma

Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 356

A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer

Boiarsky, D., Tewari, A. K., Gulhan, D. C., Bakouny, Z., Ananda, G., Savignano, H., Lakshminarayanan, G., McClure, H. M., Silver, R., Choueiri, T. K., et al. (2024) · The Prostate

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 4